Shopping Cart 0
Cart Subtotal
USD 0

Molecular Templates Inc (MTEM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Molecular Templates Inc (MTI), formerly Threshold Pharmaceuticals Inc, is a clinical-stage oncology company that discovers and develops biologic therapeutics for cancer. The company's pipeline products include MT-3724, MT-4019, MT-5111, MT-5050 and MT-6868. Its lead product MT-3724, a fusion protein, is designed for the treatment of Non-Hodgkin Lymphoma; and MT-4019 is used for the treatment of multiple myeloma. The company also develops Engineered Toxin Bodies (ETBs) for the treatment of breast cancer, melanoma and allogeneic stem cell transplantation. The company develops ETBs for various targets including CD20, CD38, HER2, and PD-L1. MTI is headquartered in Austin, Texas, the US.

Molecular Templates Inc (MTEM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Molecular Templates Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Molecular Templates Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Molecular Templates Raises USD40 million in Venture Financing 12

Molecular Templates Raises Additional USD3.5 Million in Series C Financing 14

Molecular Templates Raises USD7 Million in Venture Financing 15

Molecular Templates Raises USD 8.5 Million In Series C Financing 16

Partnerships 17

Molecular Templates Enters into Agreement with Takeda Pharma 17

AbCheck and Molecular Templates Enter into Agreement 18

Takeda Pharma Enters into Research Agreement with Molecular Templates 19

Molecular Templates Enters into Research Agreement with MD Anderson Cancer Center 20

Molecular Templates Enters into Agreement with Veristat 21

Merger 22

Molecular Templates Merges with Threshold Pharma 22

Equity Offering 24

Molecular Templates Raises USD52 Million in Public Offering of Shares 24

Molecular Templates Files Registration Statement to Raise Funds through Public Offering of Shares 26

Molecular Templates Raises USD20 million in Equity Financing 27

Acquisition 28

Threshold Pharma Acquires Molecular Templates 28

Molecular Templates Inc-Key Competitors 30

Molecular Templates Inc-Key Employees 31

Molecular Templates Inc-Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 33

Strategy And Business Planning 33

Sep 21, 2018: Takeda and Molecular Templates partner on protein-based cancer therapy 33

Financial Announcements 34

Aug 09, 2018: Molecular Templates reports second quarter 2018 financial results 34

May 14, 2018: Molecular Templates Announces First Quarter 2018 Financial Results 36

Mar 28, 2018: Molecular Templates Announces Fourth Quarter 2017 Financial Results 37

Nov 14, 2017: Molecular Templates Reports Third Quarter 2017 Financial Results 39

Corporate Communications 41

Nov 14, 2017: Molecular Templates Strengthens Management Team with Appointment of Adam Cutler as Chief Financial Officer 41

Product News 43

10/24/2017: OBI Pharma Announces Presentation on OBI-3424 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 43

Product Approvals 44

Jul 09, 2018: OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC) 44

Apr 18, 2018: OBI Pharma Announces FDA Clearance of OBI-3424 IND Application for A Phase I/II Study Targeting AKR1C3 Solid Tumors 45

Clinical Trials 46

Mar 15, 2018: New Data on Molecular Templates' Engineered Toxin Bodies to be Presented at the American Association of Cancer Research Annual Meeting 2018 46

Oct 29, 2017: OBI Pharma announces OBI-3424 results from the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 47

Jun 13, 2017: Threshold Pharmaceuticals Announces First Patient Dosed in Immunotherapy Clinical Trial of Evofosfamide and Ipilimumab 48

Mar 30, 2017: Molecular Templates Announces Presentation on MT-4019 at the 2017 American Association for Cancer Research Annual Meeting 49

Other Significant Developments 50

Jan 05, 2018: Molecular Templates Provides Corporate Update and Outlines 2018 Milestones 50

Appendix 51

Methodology 51

About GlobalData 51

Contact Us 51

Disclaimer 51


List Of Figure

List of Figures

Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Molecular Templates Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Molecular Templates Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Molecular Templates Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Molecular Templates Raises USD40 million in Venture Financing 12

Molecular Templates Raises Additional USD3.5 Million in Series C Financing 14

Molecular Templates Raises USD7 Million in Venture Financing 15

Molecular Templates Raises USD 8.5 Million In Series C Financing 16

Molecular Templates Enters into Agreement with Takeda Pharma 17

AbCheck and Molecular Templates Enter into Agreement 18

Takeda Pharma Enters into Research Agreement with Molecular Templates 19

Molecular Templates Enters into Research Agreement with MD Anderson Cancer Center 20

Molecular Templates Enters into Agreement with Veristat 21

Molecular Templates Merges with Threshold Pharma 22

Molecular Templates Raises USD52 Million in Public Offering of Shares 24

Molecular Templates Files Registration Statement to Raise Funds through Public Offering of Shares 26

Molecular Templates Raises USD20 million in Equity Financing 27

Threshold Pharma Acquires Molecular Templates 28

Molecular Templates Inc, Key Competitors 30

Molecular Templates Inc, Key Employees 31

Molecular Templates Inc, Subsidiaries 32

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Molecular Templates Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.